SAN FRANCISCO -- Lotte Biologics will begin production of its antibody-drug conjugates at its US plant by the first quarter of 2025, according to its CEO Richard Lee, who spoke at a meeting with reporters on Monday, held on the sidelines of the J.P. Morgan Healthcare Conference. As ADCs have emerged as a promising class of treatments, the Korean contract drug manufacturer has received a myriad of requests from potent...